Goldman Sachs resumed coverage of Avidity Biosciences (RNA) with a Buy rating and $55 price target The firm expects clarity over the next 12-18 months on the company’s regulatory outlook.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RNA:
- Avidity Biosciences’ Promising Phase 3 Study on FSHD Treatment: Market Implications
- Lyft upgraded, Block assumed: Wall Street’s top analyst calls
- Avidity Biosciences initiated with an Outperform at Bernstein
- Avidity, BridgeBio, Coty, SAGE, Alkermes: Trending by Analysts
- Avidity Biosciences: Strong Market Position and Future Potential Justify Buy Rating